TY - JOUR
T1 - Carboplatin and docetaxel in advanced non-small-cell lung cancer
T2 - Results of a multicenter phase II study
AU - Ramalingam, Sakkaraiappan
AU - Dobbs, Tracy W.
AU - Einzig, Avi I.
AU - Wojtowicz-Praga, Slawomir
AU - Cascino, Marianne
AU - Bonomi, Phillip
AU - Belani, Chandra P.
N1 - Funding Information:
This work was supported in part by Aventis Pharmaceuticals Inc.
PY - 2004/5
Y1 - 2004/5
N2 - Background: To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer. Methods: In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1) were treated with the combination of carboplatin AUC 5 mg/ml·min and docetaxel 80 mg/m 2 administered once every 3 weeks. Results: A total of 45 patients were accrued to the study. The median age was 62 years and adenocarcinoma was the most common histology. Patients received a median of four cycles of chemotherapy. The objective response rate was 29% with a median survival of 11.9 months among evaluable patients. The 1-year survival rate was 47%. Febrile neutropenia (17%) was the most common hematological toxicity associated with the regimen whereas grade 3 fatigue (4%) was the major nonhematological toxicity. Conclusions: The combination of carboplatin plus docetaxel is well tolerated and is effective for the treatment of patients with previously untreated advanced or metastatic non-small-cell lung cancer.
AB - Background: To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer. Methods: In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1) were treated with the combination of carboplatin AUC 5 mg/ml·min and docetaxel 80 mg/m 2 administered once every 3 weeks. Results: A total of 45 patients were accrued to the study. The median age was 62 years and adenocarcinoma was the most common histology. Patients received a median of four cycles of chemotherapy. The objective response rate was 29% with a median survival of 11.9 months among evaluable patients. The 1-year survival rate was 47%. Febrile neutropenia (17%) was the most common hematological toxicity associated with the regimen whereas grade 3 fatigue (4%) was the major nonhematological toxicity. Conclusions: The combination of carboplatin plus docetaxel is well tolerated and is effective for the treatment of patients with previously untreated advanced or metastatic non-small-cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=2142643683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2142643683&partnerID=8YFLogxK
U2 - 10.1007/s00280-003-0752-3
DO - 10.1007/s00280-003-0752-3
M3 - Article
C2 - 15132135
AN - SCOPUS:2142643683
SN - 0344-5704
VL - 53
SP - 439
EP - 444
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 5
ER -
